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Abstract
Background: The efficacy of crizotinib treatment for recurring EML4-ALK-positive non-
small cell lung cancer (NSCLC) previously treated with alectinib is unclear. Based on our
preclinical findings regarding hepatocyte growth factor/mesenchymal epithelial transition
(MET) pathway activation as a potential mechanism of acquired resistance to alectinib,
we conducted a phase II trial of the anaplastic lymphoma kinase/MET inhibitor,
crizotinib, in patients with alectinib-refractory, EML4-ALK-positive NSCLC.
Methods: Patients with ALK-rearranged tumors treated with alectinib immediately
before enrolling in the trial received crizotinib monotherapy. The objective response
rate was the primary outcome of interest.
Results: Nine (100%) patients achieved a partial response with alectinib therapy with
a median treatment duration of 6.7 months. Crizotinib was administered with a
median treatment interval of 50 (range, 20–433) days. The overall response rate was
33.3% (90% confidence interval [CI]: 9.8–65.5 and 95% CI: 7.5–70.1), which did not
reach the predefined criteria of 50%. Two (22%) patients who achieved a partial
response had brain metastases at baseline. Progression-free survival (median,
2.2 months) was not affected by the duration of treatment with alectinib. The median
survival time was 24.1 months. The most common adverse events were an increased
aspartate transaminase/alanine transaminase (AST/ALT) ratio (44%) and appetite loss
(33%); one patient developed transient grade 4 AST/ALT elevation, resulting in treat-
ment discontinuation. Other adverse events were consistent with those previously
reported; no treatment-related deaths occurred.
Conclusions: Although the desired response rate was not achieved, crizotinib mon-
otherapy following treatment with alectinib showed efficacy alongside previously
described adverse events.
K E YWORD S
Alectinib, anaplastic lymphoma kinase, crizotinib, drug therapy, non-small cell lung carcinoma
INTRODUCTION
The discovery of echinoderm microtubule-associated
protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK)†These authors contributed equally to this work.
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fusion driver oncogenes has led to an evolution in treatment
for advanced non-small-cell lung cancer (NSCLC)1 and epi-
dermal growth factor receptor (EGFR)-mutant tumors.2
Crizotinib, the first ALK-tyrosine kinase inhibitor (TKI),
has been associated with a significant survival advantage
compared to standard cytotoxic chemotherapy in random-
ized trials.3,4 Subsequently, other ALK-TKIs have been
introduced into clinical practice. Among them, alectinib, a
relatively potent and selective ALK-TKI, is associated with
substantial improvement in patient survival compared to
that observed with crizotinib.5,6 In fact, the National Com-
prehensive Cancer Network guidelines7 now recommend
alectinib as first-line ALK-TKI monotherapy for ALK-
rearranged advanced NSCLC.
However, similar to other molecular targeted therapies,
alectinib is associated with the risk of developing treatment-
resistant disease.8–10 The mechanism of acquired resistance
to crizotinib includes the development of secondary muta-
tions in the ALK kinase domain,6,11–15 ALK gene
amplification,11 and bypass track activation.13–16 Recently,
our group17 has shown that alectinib-resistant cell lines were
characterized by mesenchymal epithelial transition (MET)
activation induced by autocrine stimulation with hepatocyte
growth factor (HGF). Moreover, once the HGF/MET path-
way was activated, the cells were strongly sensitive to
crizotinib in preclinical models.18 Patients with acquired
resistance to alectinib, who achieved MET signaling activa-
tion, subsequently responded to crizotinib.19
The efficacy of crizotinib for recurring EML4-ALK-positive
NSCLC previously treated with alectinib is unclear. With this
background, we conducted a single-arm phase II trial to eval-
uate the efficacy and safety of crizotinib monotherapy in
patients with ALK-positive, alectinib-resistant NSCLC.
METHODS
Study design, participants, and intervention
Patients were eligible for this trial if they were aged
≥20 years, and had an Eastern Cooperative Oncology
Group performance status of 0 to 2 along with noncurable
stage IIIB/IV, ALK-positive NSCLC with measurable dis-
ease. ALK status was determined by immunohistochemis-
try, fluorescence in situ hybridization, or a reverse
transcription-polymerase chain reaction test. Patients were
ALK-TKI treatment-naïve except for alectinib therapy.
Patients with documented progressive disease (PD) during
alectinib monotherapy and those with prior use of cyto-
toxic chemotherapy were included. Patients were excluded
if they had symptomatic central nervous system metastases
or a history of other malignancies. Patients with uncon-
trolled concurrent illness—including active interstitial
pneumonia, pleural or pericardial effusion, or ascites—
were also excluded.
Crizotinib monotherapy was administered orally at a
dose of 250 mg twice daily until the occurrence of either PD
or unacceptable toxicity. Treatment interruption or dose
modification was allowed if clinically justified. The protocol
summary, including participant and intervention details, has
been previously described.1 Written informed consent was
obtained from all patients prior to screening. This study
conformed to the principles of the Declaration of Helsinki,
and the protocol was approved by the Institutional Review
Board of each participating site. This trial was registered in
the University Hospital Medical Information Network
(UMIN000015984).
Endpoint
The objective response rate (ORR) was the primary end-
point. Secondary endpoints included progression-free sur-
vival (PFS), overall survival (OS), and the incidence of
adverse events (AEs).
Statistical analysis
Our previous study18 showed that the HGF/MET pathway
was activated in half of the alectinib-resistant cell lines, and
a high MET expression rate was detected in 66.7% of ALK-
positive NSCLC patients.20 Thus, we expected an ORR of
50%. Since response to cytotoxic therapy was observed in
approximately 20% of ALK-positive NSCLC cases,21 our
lower limit of interest was fixed at 15%. The estimated
accrual number was nine patients using Simon’s minimax
design with a one-sided α of 0.05 and ß of 0.20. In addition,




Between June 2016 and August 2018, a total of nine patients
were enrolled in this trial (Table 1). The median age of the
patients was 63 years, and the most common diagnosis was
adenocarcinoma (78%). All patients were treated with
alectinib immediately before enrolling in the trial; seven
(78%) patients received alectinib monotherapy, and two
(22%) patients were treated with one or more regimens—
including platinum-based chemotherapy—alongside
alectinib. All nine patients achieved a partial response
(PR) during alectinib therapy with a median treatment dura-
tion of 6.7 (range: 5.7–22.9) months.
Treatment delivery
The median treatment interval was 50 (range: 20–433) days
(Table 2). Treatment was interrupted in three (33%) patients
after a median duration of 14 (range: 3–44) days. Patients
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discontinued study treatment due to PD in seven (78%)
cases, and AE or transfer to another hospital in one (11%)
case each.
Efficacy
The study was continued as interim results met the preset
criteria of having at least one treatment responder among
the four initially registered patients. Three of the nine
patients responded to the study treatment; both stable dis-
ease and PD were detected in all three patients (Table 3). At
this stage, the ORR was 33.3% (90% confidence interval
[CI]: 9.8–65.5 and 95% CI: 7.5–70.1), which failed to meet
the predefined criteria. Five (56%) patients experienced a
decrease in tumor burden relative to baseline (Figure 1(a)).
Among three patients, the response time duration was 5.5,
5.9, and 14.5 months, respectively. Two (22%) patients who
achieved a PR had brain metastases at baseline. Days from
the initiation of crizotinib monotherapy was not affected by
alectinib therapy duration (paired t-test, p = 0.0411; Fig-
ure 1(b)).
For the survival analysis, the median follow-up dura-
tion was 21.2 (range: 2.8–42.6) months. The median PFS
was 2.2 (range: 1.0–14.5) months (Figure 2(a)). Finally,
the one-year OS rate and median survival time (MST)
were 66.7% and 24.1 (range: 2.8–42.6) months, respec-
tively (Figure 2(b)).
Safety
The most common AEs were episodes of gastrointestinal
toxicity and hepatic dysfunction; appetite loss and aspartate
transaminase/alanine transaminase (AST/ALT) elevation
affected 33% and 44% of patients, respectively (Table 4).
Moreover, one patient developed transient grade 4 AST/ALT
elevation, resulting in treatment discontinuation. This com-
plication was resolved with supportive care and did not
require extensive management or admission to an intensive
care unit. Myelosuppression was uncommon among
patients; however, one patient had transient grade 4 neutro-
penia. Other AEs were consistent with the safety profile of
the study agent. No treatment-related deaths were observed
during the study period.
Relapse pattern and post-progression treatment
As shown in Table 5(a), all patients experienced disease
recurrence, most commonly at the pre-existing site (67%).
T A B L E 1 Patient demographics and clinical characteristics
Clinical factors Patients (N = 9)




ECOG PS, N (%)
0 1 (11)
1 8 (89)




Tumor histology, N (%)
Adenocarcinoma 7 (78)
Unclassified 2 (22)
Brain metastases, N (%)
Yes 2 (22)
No 7 (78)
Prior systemic therapy, N (%)
Alectinib only 7 (78)
Platinum and alectinib 2 (22)
Type of sample collected (ALK-rearrangement status),
N (%)
TBB 5 (56)
CT-guided biopsy 1 (11)
Other 3 (33)




Time from diagnosis to trial registration, months
Median (range) 7.3 (6.1–105.1)
Treatment interval of alectinib monotherapy, months
Median (range) 6.7 (5.7–22.9)
Objective response to alectinib monotherapy, N (%)
PR 9 (100)
Abbreviations: ALK, anaplastic lymphoma kinase; CT, computed tomography; ECOG
PS, Eastern Cooperative Oncology Group performance status; FISH, fluorescence in
situ hybridization; IHC, immunohistochemistry; PR, partial response; RT-PCR,
reverse transcription-polymerase chain reaction; TBB, transbronchial biopsy.
TAB L E 2 Characteristics of crizotinib administration
Characteristic Patients (N = 9)
Treatment interval (days), median (range) Interruption 50 (20–433)
N (%) 3 (33)
Interval (days), median (range) 14 (3–44)
Dose reduction, N (%) 2 (22)




Transferred to another hospital 1 (11)
Abbreviations: AE, adverse event; PD, progressive disease.
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Four (44%) patients received post-progression platinum-
based therapy (Table 5(b)). The other patients received
ALK-TKIs (56%); among them, one patient continued
treatment with crizotinib beyond Response Evaluation
Criteria in Solid Tumors (RECIST)-defined PD, while
another received alectinib monotherapy as a rechallenge
regimen.
DISCUSSION
This is the first study to demonstrate the efficacy and safety
of crizotinib administered immediately after recurrence of
EML4-ALK-positive NSCLC in patients previously treated
with alectinib. In this study, the ORR was 33.3% (95% CI:
7.5–70.1), which was lower than the criterion set for the pri-
mary endpoint. Concurrently, the median PFS was
2.2 months and the MST was 24.1 months, with a one-year
OS rate of 66.7%.
T A B L E 3 Overall response





Overall response rate 3 (33.3)
90% CI: 9.8–65.5
95% CI: 7.5–70.1
Abbreviations: CI, confidence interval; CR, complete response; PD, progressive
disease; PR, partial response; SD, stable disease.
F I G U R E 1 Overall response:
(a) Waterfall plot. Y-axis represents
the percentage change from baseline
in one-dimensional measurements
(sum of the diameters of target
lesions); and (b) swimmer plot.
Duration of treatment with alectinib
(left) and crizotinib (right)
immediately before registration in
this trial. AE, adverse event; PD,
progressive disease; PR, partial
response; SD, stable disease
F I G U R E 2 Kaplan–Meier survival curves of (a) progression-free survival (PFS); and (b) overall survival (OS). The median PFS and OS were 2.2 and
24.1 months, respectively, with a median follow-up time of 21.2 months
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The ORR in this study (Table 6) was comparable to
that reported in studies of other ALK-TKIs.22–24 Second-
ary ALK mutations such as G1202R and I1171T/N/S25,26
have been proposed to account for half of the observed
alectinib resistance.25 Other mechanisms of alectinib
resistance include EGFR activation as bypass signals,27
coactivation of c-Src and MET,28 and activation of the
HGF/MET pathway.18 A combination therapy of c-Src
and MET inhibitors (i.e., saracatinib and crizotinib) is
expected for the coactivation of c-Src and MET.28 As for
the HGF/MET activation, crizotinib affects resistant
tumors via its pathway,18,19 and patients with a treatment
response reported in this study may have had such
tumors. Further, the next-generation sequencing (NGS)
panel tests will be important in clinical practice if treat-
ment strategies for alectinib-resistant tumors are
established stratified by each type of resistant mecha-
nisms. Our future study aims to elucidate the relationship
between resistance to alectinib and the mechanisms of
crizotinib action through biomarker analysis of treatment
responders.
In contrast to the ORR, the median PFS associated
with crizotinib monotherapy in this study was shorter
than that associated with other ALK-TKIs in the
alectinib-refractory setting (Table 6). This finding may be
explained by the fact that, irrespective of treatment regi-
mens, patients included in this study possessed
(by chance) rapidly progressing tumors; the duration of
prior treatment with alectinib among patients in our
series was shorter than that of other reports (median, 6.7
[range: 12.4–34.1] months) (Table 6).5 The reason why
the patients enrolled in the study had rapidly progressing
tumors may be due to the fact that this study was started
immediately after the approval of alectinib as first-line
therapy, and therefore many patients with early alectinib
resistance were enrolled. Regarding the safety profile,
although AEs resulted in treatment discontinuation in
one patient (11%), these complications were temporary
and manageable with supportive care. Furthermore, all
patients were able to receive sequential chemotherapy
after the study treatment, retaining favorable general con-
ditions (Table 5). Overall, these findings suggest that
treatment with crizotinib in this setting was tolerable.
This study has some limitations. First, the issue of
sample size should be raised. With the limited existing
preclinical and clinical data of HGF/MET pathway activa-
tion in alectinib-resistant tumors, and our decision to
place the importance on a clinically meaningful response
rate, we set the expected response rate as 50% which led
to a very small sample size. Thus this study should be
positioned as a first exploratory step to further evaluate
and confirm the efficacy of this treatment regimen, and
our results are simply hypothesis-generating. Second,
when selecting our target population, we did not consider
different mechanisms of alectinib resistance. This was also
a limitation of previous studies evaluating ceritinib,
lorlatinib, and brigatinib (Table 6); the reported efficacy
of each drug was limited in each study. Following the suc-
cessful development of osimertinib for the treatment of
secondary T790M-positive tumors among those with
relapsed EGFR-mutated NSCLCs,29 future studies should
involve biomarker-selected populations of tumors refrac-
tory to alectinib.
In summary, treatment with crizotinib following relapse
after alectinib therapy in ALK-positive NSCLC patients was
associated with moderate efficacy and manageable AEs.
Although our study did not meet its predefined efficacy
criteria, it offers potential study implications towards future
studies and preliminary insight regarding treatment strate-
gies in patients resistant to alectinib.
T A B L E 4 Toxicity profiles
Event Any grade, N (%) Grade ≥ 3, N (%)
Neutropenia 1 (11) 1 (11)
Anemia 1 (11) 0 (0)
Creatinine elevation 3 (33) 0 (0)
Fatigue 1 (11) 0 (0)
Fever 3 (33) 0 (0)
Appetite loss 3 (33) 2 (22)
Nausea/vomiting 2 (22) 1 (11)
Constipation 3 (33) 0 (0)
Diarrhea 4 (44) 0 (0)
Flashing lights 6 (67) 0 (0)
Dysgeusia 4 (44) 0 (0)
Edema 1 (11) 0 (0)
AST/ALT elevation 4 (44) 1 (11)
Hyperbilirubinemia 1 (11) 1 (11)
Pneumonitis 0 (0) 0 (0)
Note: No treatment-related deaths were observed.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.
T A B L E 5 Recurrence sites and post-progression therapy
Patients, N (%)
(a) Recurrence sites
Pre-existing sites 6 (67)
New lesions 1 (11)
Both 2 (22)
(b) Subsequent post-progression therapy
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